We can help your business to:
No biopharmaceutical company can afford an expense such as non-compliance, consequences can be having a product withdrawn from the market or having a high-profile approval delayed. Setbacks associated with routine agency inspections, as well as more serious Warning Letters are costly and often result in approval delays, product recalls, harm to reputation, and adverse impact on shareholder value. VPA’s QMRC experts can help you build a sustainably compliant operation.
Meet our practice leads
John Seagrief, BSc, MBA
Practice Lead QMRC
John has extensive experience in the pharmaceutical industry gained over his years in the industry. This ranges from project management of new facility construction, facility, equipment and process validation, and staff training to operating manuf...read more